belinostat

09/01/2023 - "Belinostat's clinical effectiveness, comprising Phase I and II studies within the areas of solid and hematological cancers, has been evidenced through several investigative trials that have supported its potential to be a valuable anti-cancer drug. "
11/01/2016 - "A phase I study to determine the pharmacokinetics and urinary excretion of belinostat and metabolites in patients with advanced solid tumors."
01/01/2015 - "Several clinical trials are currently investigating the use of belinostat in different cancers and in combination with other chemotherapeutic agents."
07/01/2011 - "In this study, we aimed to determine the effectiveness of volumetric response evaluation criteria in solid tumors (volumetrics) for evaluating response in patients with thymic malignancies treated on a phase II study of belinostat. "
05/20/2011 - "Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors."

03/01/2017 - "Belinostat is a safe and effective treatment option for relapsed and refractory peripheral T-cell lymphoma, with many future applications currently being investigated."
08/10/2015 - "Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study."
12/01/2011 - "The data from these studies were analysed to summarise the progress of belinostat from Phase I to a current pivotal trial in peripheral T-cell lymphoma. "
01/01/2018 - "Hematologic toxicity is rare in relapsed patients treated with belinostat: a systematic review of belinostat toxicity and safety in peripheral T-cell lymphomas."
01/01/2018 - "Belinostat received regulatory approval in the USA on July 3, 2014, for use against peripheral T-cell lymphoma. "

01/01/2020 - "Belinostat has already been approved as a treatment for T‑cell lymphoma and 17‑AAG is undergoing clinical trials. "
08/15/2014 - "Belinostat approved for use in treating rare lymphoma."
12/01/2011 - "Belinostat: clinical applications in solid tumors and lymphoma."
01/01/2017 - "A Phase II Exploratory Study of PXD-101 (Belinostat) Followed by Zevalin in Patients with Relapsed Aggressive High-Risk Lymphoma."
06/01/2023 - "We report a young patient with highly pretreated relapsed/refractory nodal follicular helper T-cell lymphoma (angioimmunoblastic-type [nTFHL-AI]), who successfully received an allogeneic stem cell transplantation following belinostat therapy. "

01/01/2019 - "Excitingly, belinostat significantly improved depressive symptoms in patients with glioblastoma compared with control subjects. "
10/01/2016 - "To our knowledge this is the first report presenting the effects of belinostat treatment in glioblastoma cell lines."
01/01/2022 - "Final Report on Clinical Outcomes and Tumor Recurrence Patterns of a Pilot Study Assessing Efficacy of Belinostat (PXD-101) with Chemoradiation for Newly Diagnosed Glioblastoma."
10/01/2016 - "Here, we provide novel information concerning the influence of belinostat (Bel), a hydroxamate-based pan-HDAC inhibitor, on glioblastoma LN-229 and LN-18 cells. "
10/01/2016 - "Molecular and cellular effects of a novel hydroxamate-based HDAC inhibitor - belinostat - in glioblastoma cell lines: a preliminary report."

02/15/2012 - "In this study, we show that belinostat, an HDAC inhibitor with an alternative chemical scaffold, also caused a rise in cellular PC content that was detectable by (1)H and (31)P MRS in prostate and colon carcinoma cells. "
01/01/2019 - "Urothelial carcinoma cell lines treated with panobinostat and belinostat were studied to elucidate the mechanisms of benefit. "
05/15/2015 - "Paclitaxel/carboplatin with or without belinostat as empiric first-line treatment for patients with carcinoma of unknown primary site: A randomized, phase 2 trial."
05/01/2012 - "A phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study."
01/01/2019 - "In two separate phase I clinical trials testing pharmacokinetic aspects of HDAC inhibitors in advanced solid tumors, we identified one patient with advanced urothelial carcinoma who had a complete response to belinostat, and one patient with advanced urothelial carcinoma who had a partial response to panobinostat. "